Integration of innovative statistical methods using genetic data provides pharmacological insight and facilitates drug development.


No Thumbnail Available
Type
Article
Change log
Authors
Abstract

The use of genetic data can be of great benefit in drug development. When analysed with appropriate statistical methods, such resources can be leveraged to identify potential drug targets and inform experimental trials [1]. It has been shown that drug development done with the backing of genetic data is more likely to be successful [2]. Increasingly, pharmacological studies are able to harness the results of genome-wide association studies (GWAS), which test for associations between a phenotype and genetic variation across the entire genome. Such studies are rapidly expanding in terms of both size of samples and range of phenotypes [3]. Although GWAS are able to identify many genetic variants that are associated with a phenotypic trait of interest, they are not able to provide, on their own, evidence as to which of these associations are causal, or by which mechanisms these associations come about. New statistical methodology is being developed which uses genetic data to help to answer these questions.

Description
Keywords
Clozapine, Drug Development, Genome-Wide Association Study, Humans, Neutropenia, Quantitative Trait Loci
Journal Title
Br J Clin Pharmacol
Conference Name
Journal ISSN
0306-5251
1365-2125
Volume Title
Publisher
Wiley
Sponsorship
Wellcome Trust (204623/Z/16/Z)
Medical Research Council (MC_UU_00002/7)